Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955074 | 1.00 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL10066477 | 0.78 | SMN1; SMN2 (0.40) | KMT2AMEN1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL15674698 | 0.78 | SMN1; SMN2 (0.40) | KMT2AMEN1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL9955077 | 0.76 | POLB (0.46) | KMT2AMEN1MAPTPOLB | |
| SCHEMBL3709639 | 0.75 | SMN1; SMN2 (0.38) | KMT2AMEN1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL15674404 | 0.72 | ALOX5 (0.36) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL9955946 | 0.72 | ALOX5 (0.36) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL1463687 | 0.72 | SMN1; SMN2 (0.65) | KMT2AMEN1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL1463685 | 0.72 | SMN1; SMN2 (0.65) | KMT2AMEN1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL13021174 | 0.72 | MEN1 (0.68) | KMT2AMEN1ALDH1A1GPR139L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916701-B2 | Methods of making diastereomeric organic compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2655349-B1 | METHODS OF MAKING DIASTEREOMERIC ORGANIC COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-15 | — | — | EP | disclosed |
| US-20140135493-A1 | METHODS OF MAKING DIASTEREOMERIC ORGANIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135493-A1 | METHODS OF MAKING DIASTEREOMERIC ORGANIC COMPOUNDS | HSD11B1, HSD11B2, HSD17B1 | KMT2A 2536/4885MEN1 384/4885SMN1; SMN2 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.